A Cohort Study in Newly Diagnosed MZL

Fudan University

Status: Enrolling

Conditions: Marginal Zone Lymphoma

Treatments: Other: patients receive optimal treatment or follow-up according to the characteristics of the disease

Study type: Observational

Funder types: Other

Identifiers

NCT06449885

SHCA-MZL-001

Details and patient eligibility

About

Describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of marginal zone B-cell lymphoma (MZL), observe the therapeutic efficacy and safety of different treatment modalities.

Full description

Marginal zone lymphoma (MZL) originates from the marginal zone of lymphatic follicles and can occur in the spleen, lymph nodes and mucosal lymphoid tissues, and the incidence increases with age. The clinicopathological features of each subtype of MZL are heterogeneous, and their clinical manifestations, biology, etiology, and treatment are all quite heterogeneous, and there is still significant uncertainty about the optimal treatment pathway. This prospective, multicenter, cohort study aims to describe the clinical features, diagnosis and treatment status, disease course and primary outcomes of different subtypes of MZL, and to observe the therapeutic efficacy and safety of different treatment modalities.

Enrollment: 2,500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age≥ 18 years old; Male or female.
• Newly diagnosed marginal zone lymphoma by histopathology within the past 6 months (180 days) and no anti-tumor therapy (including chemotherapy, radiotherapy, and biological therapy or immunotherapy for the treatment of tumors).
• Willing to provide biological samples required for the study, including blood samples and tumor tissue.
• Voluntarily join this study and sign the informed consent form.
• Willing to accept long-term follow-up.

Exclusion criteria

• Patients with HIV infection.
• Those who cannot come to the hospital regularly for follow-up.
• Those with comorbidities and speech impairment.

Trial design

2,500 participants in 1 patient group

Newly diagnosed marginal zone lymphoma

Description:

Newly diagnosed marginal zone lymphoma，including Mucosa-associated lymphoid tissue (MALT) lymphoma, spleen MZL, and lymph node MZL, as well as primary cutaneous MZL, and pediatric NMZL.

Treatment:

Other: patients receive optimal treatment or follow-up according to the characteristics of the disease